Keyphrases
Acute Myeloid Leukemia
100%
I to
100%
Receptor Subtypes
100%
FLT3 Inhibitor
100%
FMS-like Tyrosine Kinase 3 (FLT3)
100%
Inhibitor Resistance
100%
Activin Receptor
100%
Venetoclax
100%
FLT3 mutation
44%
Acute Myeloid Leukemia Cells
33%
Leukemia Cell Lines
22%
Putative Drug Targets
11%
Leukemia
11%
Potential Therapeutics
11%
Dose Effect
11%
High Affinity
11%
Growth Arrest
11%
Novel Biomarkers
11%
Therapeutic Tool
11%
Downstream Signaling
11%
Dual Inhibitor
11%
Bcl-2 Inhibitor
11%
Molecular Docking
11%
Patient-derived Xenograft
11%
In Vitro Kinase Assay
11%
Type I Inhibitor
11%
Cell Line-derived Xenograft
11%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Receptor
100%
Activin A
100%
Venetoclax
100%
Acute Myeloid Leukemia Cell Line
22%
Biological Marker
11%
In Vitro
11%
Leukemia
11%
Xenograft
11%
Leukemia Cell
11%
Growth Disorder
11%
Kinase Assay
11%
Docking (Molecular)
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Receptor
100%
Activin A
100%
Venetoclax
100%
Leukemia
11%
Phosphotransferase
11%
Biological Marker
11%
Growth Disorder
11%
Biochemistry, Genetics and Molecular Biology
Myeloid
100%
Activin
100%
Kinase
11%
Phosphotransferase
11%
Docking (Molecular)
11%